Loading...
Market
Story
ACIP Recommends Lowering Age for Pfizer and Merck Pneumococcal Vaccines to 50
Oct 24, 2024, 12:15 AM
The Advisory Committee on Immunization Practices (ACIP) has recommended lowering the age for pneumococcal vaccination from 65 to 50 years old. This decision aims to expand access and protect more adults from pneumococcal disease, which can cause serious illnesses such as pneumonia, meningitis, and bloodstream infections. The recommendation includes the use of PREVNAR 20®, a 20-valent pneumococcal conjugate vaccine, for adults aged 50 and older. This significant update reflects the committee's efforts to address low vaccine uptake in this age group and improve public health outcomes. The vaccines recommended are made by Pfizer and Merck.
View original story
Similar markets
Capvaxive leads • 33%
Prevnar 20 leads • 33%
Equal market share • 33%
Capvaxive preferred • 33%
Prevnar 20 preferred • 33%
No preference • 33%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Yes • 50%
No • 50%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%